15693
document
Prediction of the response to citalopram and reboxetine in post-stroke depressed patients . RATIONALE AND OBJECTIVE Depression is a significant complication of stroke . The effectiveness of antidepressant drugs in the management of post-stroke depression ( PSD ) has been widely investigated . However , the choice of antidepressant drug is critically influenced by its safety and tolerability and by its effect on concurrent pathologies . Here we investigate the efficacy and safety of a selective serotonin reuptake inhibitor ( SSRI ) , citalopram , and a noradrenaline reuptake inhibitor ( NARI ) , reboxetine , in post-stroke patients affected by anxious depression or retarded depression . METHODS This was a randomized double-blind study . Seventy-four post-stroke depressed patients were diagnosed as affected by anxious or retarded depression by using a synoptic table . Randomisation was planned so that 50 % of the patients in each subgroup were assigned for 16 weeks to treatment with citalopram and the remaining 50 % were assigned to treatment with reboxetine . The Beck Depression Inventory ( BDI ) , the Hamilton Depression Rating Scale ( HDRS ) and a synoptic table were used to score depressive symptoms . RESULTS Both citalopram and reboxetine showed good safety and tolerability . Citalopram exhibited greater efficacy in anxious depressed patients , while reboxetine was more effective in retarded depressed patients . CONCLUSIONS Citalopram or other SSRIs and reboxetine may be of first choice treatment in PSD because of their good efficacy and lack of severe side effects . In addition , PSD patients should be classified according to their clinical profile ( similarly to patients affected by primary depression ) for the selection of SSRIs or reboxetine as drugs of choice in particular subgroups of patients .
15694
Intervention_Pharmacological
citalopram and reboxetine
15695
Intervention_Pharmacological
serotonin reuptake inhibitor ( SSRI ) , citalopram , and a noradrenaline reuptake inhibitor ( NARI ) , reboxetine
15696
Intervention_Pharmacological
citalopram
15697
Intervention_Pharmacological
reboxetine
15698
Intervention_Pharmacological
citalopram
15699
Intervention_Pharmacological
reboxetine
15700
Intervention_Pharmacological
reboxetine
15701
Intervention_Pharmacological
Citalopram
15702
Intervention_Pharmacological
reboxetine
15703
Outcome_Other
safety
15704
Outcome_Other
tolerability
15705
Outcome_Mental
Beck Depression Inventory ( BDI ) , the Hamilton Depression Rating Scale ( HDRS )
15706
Outcome_Mental
depressive symptoms .
15707
Outcome_Other
safety and tolerability
15708
Outcome_Physical
.
15709
Outcome_Other
greater efficacy
15710
Outcome_Physical
efficacy and lack of severe side effects .
15711
Participant_Condition
post-stroke depressed patients
15712
Participant_Condition
anxious depression
15713
Participant_Condition
retarded depression
15714
Participant_Sample-size
Seventy-four
15715
Participant_Condition
post-stroke depressed
15716
Participant_Condition
PSD